Aneurysmal subarachnoid hemorrhage (ASH) is a type of stroke that is life threatening. It exhibits high rates of fatality and permanent disability. ASH is caused due to head injury and hence, it results into stroke. According to a literature review, after ASH, approximately 33% of patients recover and live healthy life; 33% of them survive but live along with some kind of disability, and the rest of patients die.
Subarachnoid is a part between the skull and the brain. This portion is filled with the cerebrospinal fluid that protects the brain. When the blood enters this space, it increases the pressure on the brain and damages the brain cells. The cells of the brain get deprived of oxygen-rich blood, which results into stroke. Symptoms of ASH include sudden onset of severe headache, nausea, vomiting, stiff neck, sensitivity to light, blurred or double vision, loss of consciousness, and seizures. ASH is often witnessed in elderly individuals who fall and suffer a brain injury. Approximately 5%–10% cases of stroke result from ASH. The diagnosis includes CT scan, lumbar puncture, angiogram, and MRI scan.
The aneurysmal subarachnoid hemorrhage drugs market is driven by increase in elderly population and rise in the incidence of brain clots. In addition, high incidence of hypertension and chronic diseases, increase in health care spending, and favorable reimbursement scenario are expected to boost the global aneurysmal subarachnoid hemorrhage drugs market in the next few years. Furthermore, the existing market players are involved in deployment of advanced techniques and strategies to come up with innovative methods of analysis of stroke and its treatment. Also, high alcohol consumption and increase in the rate of smoking led by changes in lifestyle of people are expected to increase the risk of ASH. However, dearth of skilled professionals and high rate of side-effects associated with the use of aneurysmal subarachnoid hemorrhage drugs (such as ashes, itching, nausea, changes in appetite, and sleepiness) are expected to restraint the aneurysmal subarachnoid hemorrhage drugs market during the forecast period. On the other hand, developing nations such as China and India are expected provide attractive growth opportunities to the aneurysmal subarachnoid hemorrhage drugs market during the forecast period.
The global aneurysmal subarachnoid hemorrhage drugs market can be segmented based on drug class and region. Based on drug class, the market can be divided into calcium channel blocker, opioid analgesic, osmotic agent, anticonvulsant, stool softener, and others.
In terms of region, the global aneurysmal subarachnoid hemorrhage drugs market can be segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the maximum aneurysmal subarachnoid hemorrhage drugs market share in 2017, owing to availability of advanced health care facilities in the region. Furthermore, increase in approval of drugs and presence of a large number of manufacturers are driving the market in North America. Asia Pacific and Latin America are expected to be lucrative markets for aneurysmal subarachnoid hemorrhage drugs during the forecast period. The market in these regions is projected to expand at a rapid pace during the forecast period, owing to surge in investments by leading players to gain market share and increase in government investments in the advancement of health care in these regions.
Key players operating in the global aneurysmal subarachnoid hemorrhage drugs market are Edge Therapeutics, Inc., Mylan N.V., Arbor Pharmaceuticals Inc., Purdue Pharma L.P., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Orexo AB, Pfizer Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.